Phase l study into Huntington’s Disease – Europe
CCA was engaged by a European biotech to manage UK Ethics submissions and field operations for an exploratory phase I clinical study in a rare disease indication.
The company was appointed to deliver clinical monitoring and management of the ethics committee for the trial and was in charge of handling all communications and management relating to the trial site. We took over from another CRO part-way through this early-phase trial, but still successfully completed the study on time and within budget.
The sponsor was able to achieve study completion on target.